GSK’s anaemia drug gets FDA advisory committee support for patients on dialysis
A final decision for daprodustat by the FDA is expected by 1 February 2023
Read More
Tag: kidney disease
First treatment option indicated for CKD in Scotland for 20 years
NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy
Read More
Mission Therapeutics launches clinical trial for kidney disease therapy
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial
Read More
Kidney Research UK pledges support to Accelerate@Babraham initiative
Accelerate@Babraham supports early-stage life sciences ventures within the Babraham Research Campus’ community
Read More
New COVID-10 guidelines for CKD and interstitial lung disease
The guidelines should help healthcare professionals decide what care to provide for people without COVID-19 infection or with confirmed or suspected infection safely while making the best use of NHS resources
Read More
Invokana hits endpoints in cardiovascular trial
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
Read More
Gilead, Goldfinch to team up against kidney disease
The multi-year collaboration will expand the scope of Goldfinch’s proprietary Kidney Genome Atlas.
Read More
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
Read More
UK study to investigate kidney disease progression
A large-scale observational study of chronic kidney disease (CKD) is due to launch in general practices this month, involving 3,205 Oxfordshire residents and led by Oxford University researchers.
Read More
GSK kicks off Phase III programme for daprodustat
GlaxoSmithKline has begun Phase III development of daprodustat, testing its potential as a treatment for anaemia associated with chronic kidney disease (CKD).
Read More
Bayer and Evotec form kidney disease research pact
Bayer and Evotec have signed a five-year, multi-target research pact to develop clinical candidates for the treatment of chronic kidney diseases.
Read More
AZ trials diabetes drug Forxiga in kidney disease, heart failure
AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga (dapagliflozin) exploring its potential beyond the drug’s approved diabetes indication.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
